{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115735","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.749660+00:00","generated_at":"2026-06-08T09:33:37.552950+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Natera Q3 revenue $268.3M (+27% YoY), raises FY2023 revenue and margin guidance, reduces cash burn","bullets":["Revenue $268.3M, up 27% YoY; product revenue $265.2M, up 33% YoY.","Processed ~626,000 tests (+21% YoY); oncology tests ~89,000 (+68% YoY) with 81,000 Signatera clinical units (+85%).","Net loss improved to $109.0M ($0.95/share) from $121.5M ($1.25/share) in Q3 2022.","Raises 2023 revenue guidance to $1.035B-$1.05B (from $1.015B-$1.035B); cash burn reduced to $260M-$280M (from $300M-$325M).","Cash, equivalents and investments $936.6M; total debt $363.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115735","json":"https://secwatch.observer/filing/0001104659-23-115735.json","markdown":"https://secwatch.observer/filing/0001104659-23-115735.md","text":"https://secwatch.observer/filing/0001104659-23-115735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923115735/0001104659-23-115735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923115735/tm2329774d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:33:37.552950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b90ba60f4e5530c5fd13ced5c90454d4ccca0606","claim":"Natera, Inc. reported third quarter ended September 30, 2023 results: revenue $268.3 million, net income net loss of $109.0 million, EPS ($0.95) per diluted share. Guidance raised.","evidence_excerpt":"cell-free DNA testing , today reported financial results for the third quarter ended September 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $268.3 million in the third quarter of 2023, compared to $210.6 million in the third quarter of 2022, an increase of approximately 27%. Product revenues grew approximately 33% over the same","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923115735/0001104659-23-115735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$268.3 million"},{"label":"Net income","value":"net loss of $109.0 million"},{"label":"EPS","value":"($0.95) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}